MAPK3 and cancer: TPM1 is recognized as a tumor suppressor in a range of cancer types.180, 181, 182 So, regarding the fact that the AZGP1P2/UBA1/RBM15-TPM1-ERK1/2 axis regulates prostate CSCs to control docetaxel treatment resistance in castration-resistant prostate cancer, it can serve as a new target for gene therapy of this cancer.104